Economic burden of ventilator-associated pneumonia based on total resource utilization

Marcos I. Restrepo, Antonio Anzueto, Alejandro C. Arroliga, Bekele Afessa, Mark J. Atkinson, Ngoc J. Ho, Regina Schinner, Ronald L. Bracken, Marin H. Kollef

Research output: Contribution to journalArticle

78 Scopus citations

Abstract

OBJECTIVES. To characterize the current economic burden of ventilator-associated pneumonia (VAP) and to determine which services increase the cost of VAP in North American hospitals. DESIGN AND SETTING. We performed a retrospective, matched cohort analysis of mechanically ventilated patients enrolled in the North American Silver-Coated Endotracheal Tube (NASCENT) study, a prospective, randomized study conducted from 2002 to 2006 in 54 medical centers, including 45 teaching institutions (83.3%). METHODS. Case patients with microbiologically confirmed VAP (n = 30 ) were identified from 542 study participants with claims data and were matched by use of a primary diagnostic code, and subsequently by the Acute Physiology and Chronic Health Evaluation II score, to control patients without VAP ( n = 90 ). Costs were estimated by applying hospital-specific cost-to-charge ratios based on all-payer inpatient costs associated with VAP diagnosis-related groups. RESULTS. Median total charges per patient were $198,200 for case patients and $96,540 for matched control patients ( P < .001 ); corresponding median hospital costs were $76,730 for case patients and $41,250 for control patients ( P = .001 ). After adjusting for diagnosis-related group payments, median losses to hospitals were $32,140 for case patients and $19,360 for control patients (P = .151 ). The median duration of intubation was longer for case patients than for control patients (10.1 days vs 4.7 days; P < .001), as were the median duration of intensive care unit stay (18.5 days vs 8.0 days; ) and the median duration of hospitalization (26.5 days vs 14.0 days; P < .001 ). Examples of services likely to be directly related to VAP and having higher median costs for case patients were hospital care (P< .001) and respiratory therapy (P<.05). CONCLUSIONS. VAP was associated with increased hospital costs, longer duration of hospital stay, and a higher number of hospital services being affected, which underscores the need for bundled measures to prevent VAP. TRIAL REGISTRATION. NASCENT study ClinicalTrials.gov Identifier: NCT00148642.

Original languageEnglish (US)
Pages (from-to)509-515
Number of pages7
JournalInfection Control and Hospital Epidemiology
Volume31
Issue number5
DOIs
StatePublished - May 1 2010

ASJC Scopus subject areas

  • Epidemiology
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Economic burden of ventilator-associated pneumonia based on total resource utilization'. Together they form a unique fingerprint.

  • Cite this

    Restrepo, M. I., Anzueto, A., Arroliga, A. C., Afessa, B., Atkinson, M. J., Ho, N. J., Schinner, R., Bracken, R. L., & Kollef, M. H. (2010). Economic burden of ventilator-associated pneumonia based on total resource utilization. Infection Control and Hospital Epidemiology, 31(5), 509-515. https://doi.org/10.1086/651669